Neoadjuvant immunotherapy improves outlook in high-risk melanoma

Bookmark and Share
Published: 14 Sep 2022
Views: 49
Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA

Dr Sapna Patel speaks to ecancer about the SWOG S1801 trial which studied the use of neoadjvuant versus adjuvant pembrolizumab to treat resected stage III-IV melanoma. 

The study found that using single-agent pembrolizumab, neo-adjuvant immunotherapy improves event free survival compared to adujavnt therapy in high-risk resectable melanoma.

The findings from S1801 trial have important implications about the sequence of treatment for patients with melanoma and other cancers that respond to immune checkpoint blockade.